ReviewOncotarget2016
Mast cell sarcoma: new cases and literature review.
Review in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 54 citations in OpenAlex.
- Impact of Molecular Evaluations in the Biology, Diagnosis, and Prognostication of Patients With Mastocytosis.The journal of allergy and clinical immunology. In practice · 2026Review
- Fever: Harmless Heat or a Deadly Inferno? Unmasking Hemophagocytic Lymphohistiocytosis and Beyond: A Rare Case of Mast Cell Sarcoma and Overview of HLH.Journal of hematology · 2025Article
- Mast cell sarcoma with KIT p.D816V mutation and concurrent systemic mastocytosis.Journal of hematopathology · 2024Article
- Primary Mast Cell Sarcoma of the Maxillary Sinus and Gingiva Mimicking Malignant Neuroendocrine Tumor: A Case Report.Head and neck pathology · 2024Article
- Intracranial invasion of a mast cell tumour in a dog: A case report and review of the literature.Veterinary medicine and science · 2024Review
- Current Challenges in the Diagnosis of Pediatric Cutaneous Mastocytosis.Diagnostics (Basel, Switzerland) · 2023Review
- Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.International journal of molecular sciences · 2023Review
- Mast Cell Leukemia: An Update with a Practical Review.Cancers · 2023Review
- Aptamer-based Advances in Skin Cancer Research.Current medicinal chemistry · 2023Review
- Mast Cells and Vitamin D Status: A Clinical and Biological Link in the Onset of Allergy and Bone Diseases.Biomedicines · 2022Review
- Irritable bowel syndrome is strongly associated with the primary and idiopathic mast cell disorders.Neurogastroenterology and motility · 2022Article
- Case report of a clinically indolent but morphologically high-grade cutaneous mast cell tumor in an adult: Atypical cutaneous mastocytoma or mast cell sarcoma?Journal of cutaneous pathology · 2021Article
- Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.HemaSphere · 2021Review
- Mastocytosis and Mast Cell Activation Disorders: Clearing the Air.International journal of molecular sciences · 2021Review
- Systemic mastocytosis revisited with an emphasis on skeletal manifestations.La Radiologia medica · 2021Review
- Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021.International journal of molecular sciences · 2021Review
- The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review.Pathobiology : journal of immunopathology, molecular and cellular biology · 2020Review
- Allogeneic Hematopoietic Stem Cell Transplantation in a Rare Case of Tonsillar Mast Cell Sarcoma.Frontiers in oncology · 2020Article
- Spontaneous globule leukocyte tumor accompanied by inflammatory cells in a Wistar Hannover rat.Journal of toxicologic pathology · 2019Article
- Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mast cell sarcoma (MCS) is a rare form of mastocytosis characterized by the presence of solid tumor(s) comprising malignant mast cells that harbor destructive infiltration capability and metastatic potential. Here, we present an extensive literature review and report on 23 cases of MCS, including 3 new cases from the French National Reference Center for Mastocytosis. From our analysis, it appears that MCS can occur at any age. It can manifest de novo or, to a lesser extent, may evolve from a previously established mastocytosis. Bone tumor is a frequent manifestation, and symptoms of mast cell activation are rare. Histological diagnosis can be difficult because MCS is frequently composed of highly atypical neoplastic mast cells and can thus mimic other tumors. Unexpectedly, the canonical KIT D816V mutation is found in only 21% of MCS; therefore, complete KIT gene sequencing is required. The prognosis of patients with MCS is poor, with a median survival time of less than 18 months, and progression to mast cell leukemia is not unusual. Because conventional chemotherapies usually fail, the role of targeted therapies and bone marrow transplantation warrants further investigation in such aggressive neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.